Rezolute (NASDAQ:RZLT) & BetterLife Pharma (OTCMKTS:PVOTF) Head to Head Contrast

Rezolute (NASDAQ:RZLT) and BetterLife Pharma (OTCMKTS:PVOTF) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability and analyst recommendations.

Profitability

This table compares Rezolute and BetterLife Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-69.83%	-62.16%
BetterLife Pharma	N/A	-205.15%	-147.23%

Institutional & Insider Ownership

83.0% of Rezolute shares are owned by institutional investors. 18.4% of Rezolute shares are owned by insiders. Comparatively, 34.8% of BetterLife Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Rezolute and BetterLife Pharma”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$68.46 million	($1.27)	-3.61
BetterLife Pharma	N/A	N/A	-$14.78 million	N/A	N/A

Analyst Recommendations

This is a summary of recent ratings and target prices for Rezolute and BetterLife Pharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	0	0	8	0	3.00
BetterLife Pharma	0	0	0	0	0.00

Rezolute presently has a consensus price target of $24.13, indicating a potential upside of 425.60%. Given Rezolute’s stronger consensus rating and higher probable upside, equities analysts plainly believe Rezolute is more favorable than BetterLife Pharma.

Summary

Rezolute beats BetterLife Pharma on 6 of the 9 factors compared between the two stocks.

About Rezolute

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

About BetterLife Pharma

BetterLife Pharma, Inc. is an early stage pharmaceutical company, which engages in the development and commercialization of therapeutic pharmaceutical and nutraceutical products. It also offers drug delivery platform technologies. Its product lines include capsules, tablets, and softgels; bulk powder; stick packs; beverages; oral solutions; lotions, creams, and gels; pet food additives; gum, mints, and candies; and sexual health products. It distributes its product under the Pivot Naturals brand. The company was founded on June 10, 2002 and is headquartered in Vancouver, Canada.